A Phase 2/3 interventional study of naloxone and Placebo in Heart Arrest, sponsored by Region Skane. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by Region Skane · Phase 2/3, Interventional, and Treatment
The goal of this clinical trial is to learn if the drug naloxone in addition to cardiopulmonary resuscitation improves outcomes of in-hospital cardiac arrets. The main questions it aims to answer are:
Does naloxone improve survival after the cardiac arrest? Does naloxone improve functional outcome in survivors of cardiac arrest? Does naloxone improve health related quality of life after the cardiac arrest? How common are adverse reactions to naloxone when administered during cardiopulmonary resuscitation.
Researchers will compare naloxone to a placebo (a look-alike substance that contains no drug) to see if naloxone works during cardiac arrest.
926 studies on the registry are indexed under Heart Arrest; 226 are open to participants now.
This study's planned enrollment of 850 is above the median of 100 across 518 interventional studies indexed under Heart Arrest.
Browse Heart Arrest studies →Region Skane is the lead sponsor of 386 studies on the registry; 122 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: naloxone
Drug: Placebo
2 mg naloxone administered intravenously or intraosseously
0.9% saline administered intravenously or intraosseously
30-day survival
proportion of patients alive
Time frame: 30 days after the cardiac arrest
No study locations are listed for this record.
Plan to share: Yes — After the publication of the last results, all de-identified individual patient data will be made available for data sharing. Data will be available for any research with ethical approval and with methodology approved by the steering committee of the current trial. Authorship of publications emerging from the shared data will follow standard authorship guidelines
Supporting information: Study protocol, Statistical analysis plan
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Naloxone